Thursday, January 26, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

BARDA Backs Emergent Biosolutions’ NuThrax Vaccine

by Global Biodefense Staff
March 30, 2015

Advanced development is underway on an improved anthrax vaccine that could provide protection in fewer doses than the currently licensed anthrax vaccine and so may be more cost-effective to stockpile, Dr. Nicole Lurie, assistant secretary for preparedness and response for the U.S. Department of Health and Human Services (HHS) announced last week.

The development work will be done through a 30-month, $31 million agreement between HHS’ Biomedical Advanced Research and Development Authority (BARDA) and Emergent BioSolutions Inc. of Gaithersburg, Maryland.

BARDA will provide funding and technical assistance for the advanced development of NuThrax, (anthrax vaccine adsorbed with CPG 7909 adjuvant), also known as AV7909, including non-clinical studies, product development, and manufacturing to support phase 3 safety studies with larger groups than previous studies.

“Anthrax remains a national health security threat, and we’re striving to develop an anthrax vaccine that affords immunity sooner and with fewer doses,” explained BARDA Director Robin Robinson, Ph.D. “If it works, this vaccine may help achieve better preparedness at a lower cost.”

“Emergent looks forward to working with BARDA to advance the development of NuThrax towards a Phase 3 study. We are committed to addressing the U.S. government’s desire for a next generation anthrax vaccine with an enhanced product profile that includes requiring fewer doses, eliciting a higher immune response, and dispensing the need for cold chain with a dry formulation,” said Adam Havey, executive vice president and president biodefense division of Emergent BioSolutions.

Nuthrax is a modified formulation of BioThrax, an anthrax vaccine manufactured by Emergent that requires three doses to protect against anthrax. BioThrax is licensed by the U.S. Food and Drug Administration for use prior to exposure to anthrax and could be used after exposure with emergency use authorization from the FDA. BioThrax is stockpiled in the Centers for Disease Control and Prevention’s Strategic National Stockpile, and BARDA is supporting additional work under Project BioShield to apply for label expansion for post-exposure use.

Early development of NuThrax was sponsored by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) and the Department of Defense. This early work included manufacturing process development, critical non-clinical studies, and completion of phase 1 and 2 clinical studies.

NuThrax represents the successful transition of a vaccine from early development under NIAID into advanced development under BARDA and resulted from more than six years of collaboration on the vaccine’s development between the two HHS agencies.

Tags: AnthraxASPRBARDAEmergency Use AuthorizationHHSStrategic National StockpileThermostabilityVaccines

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC